FOXO4-DRI — Research Overview
Chemical Name: FOXO4 D-Retro-Inverso peptide Also Known As: FOXO4-DRI, FOXO4-p53 senolytic peptide Structure: Synthetic peptide derived from the p53-interaction domain of the FOXO4 forkhead transcription factor, modified using the D-retro-inverso (DRI) approach in which all L-amino acids are replaced by their D-enantiomers and the peptide sequence is reversed. This dual modification produces a molecule that is stereochemically stable against proteolytic degradation while retaining the binding specificity of the original sequence. Approximate Length: 29 amino acids Development Origin: Developed at Erasmus University Medical Center, Rotterdam, Netherlands, by the group of Dr. Peter de Keizer, published in Cell 2017. Category: Senolytic research peptide / FOXO4-p53 protein-protein interaction inhibitor / cell-penetrating peptide / aging research compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is FOXO4-DRI?
FOXO4-DRI is a synthetic senolytic peptide designed to selectively eliminate senescent cells by disrupting a specific protein-protein interaction that senescent cells depend on for their survival. It was developed at Erasmus University Medical Center and published in the journal Cell in 2017 as the first cell-penetrating peptide senolytic to demonstrate reversal of multiple age-related tissue deficits in vivo.
To understand what FOXO4-DRI does, it is necessary to first understand the biology of cellular senescence — a field that has become one of the most active areas of aging and longevity research in contemporary biomedical science.
Cellular senescence is a state of permanent cell cycle arrest that cells enter in response to various forms of stress including DNA damage, oxidative stress, replicative exhaustion, and oncogene activation. Senescent cells stop dividing but remain metabolically active. Rather than undergoing apoptosis (programmed cell death) as damaged cells normally would, senescent cells acquire a pro-inflammatory secretory program known as the senescence-associated secretory phenotype (SASP) — a mixture of cytokines, chemokines, growth factors, and matrix metalloproteinases that they chronically secrete into surrounding tissue.
In young organisms, senescent cells serve important transient functions: they promote wound healing, suppress tumor formation, and signal to the immune system for their own clearance. In aging organisms, the immune system’s capacity to clear senescent cells declines, and senescent cells accumulate in tissues throughout the body. The SASP produced by accumulated senescent cells drives chronic low-grade inflammation — sometimes called inflammaging — and has been causally linked in published research to multiple age-related tissue pathologies including fibrosis, metabolic dysfunction, musculoskeletal decline, kidney disease, and reduced regenerative capacity.
Compounds designed to selectively eliminate senescent cells without harming normal healthy cells are called senolytics. FOXO4-DRI represents a mechanistically distinct senolytic approach: rather than broadly inhibiting pro-survival pathways shared by senescent and non-senescent cells, it targets a protein-protein interaction (FOXO4 and p53) that is specifically upregulated in senescent cells and essential to their apoptosis resistance.
The D-Retro-Inverso Modification — Why It Matters
Standard peptides composed of natural L-amino acids are rapidly degraded by ubiquitous proteolytic enzymes in biological fluids and intracellular environments, giving them half-lives measured in minutes that limit their therapeutic utility. The D-retro-inverso modification addresses this by substituting all L-amino acids with their D-enantiomers (mirror-image amino acids not recognized by most proteases) and simultaneously reversing the peptide sequence. This dual modification preserves the three-dimensional shape of the functional binding surface — allowing the DRI peptide to interact with the same protein targets as its L-amino acid parent — while conferring resistance to enzymatic degradation that extends the functional intracellular half-life from minutes to several hours.
This modification is what makes FOXO4-DRI biologically active at the protein-protein interaction interface rather than being degraded before reaching its intracellular target. The same DRI approach has been used in other peptides that have reached clinical trials, establishing precedent for its tolerability and utility.
The FOXO4-p53 Axis in Senescent Cell Survival
In normal proliferating cells, the tumor suppressor p53 functions as a master guardian of genomic integrity. When DNA damage is detected, p53 triggers either cell cycle arrest (to allow repair) or apoptosis (if repair is impossible). This pro-apoptotic function of p53 is what normally eliminates damaged cells before they can become senescent.
In senescent cells, a paradoxical situation develops. p53 is present and active — often in a phosphorylated form (p53 phosphorylated at serine 15) that would normally drive apoptosis — but it is prevented from executing that apoptotic program by its interaction with FOXO4. In senescent cells, FOXO4 expression is markedly upregulated compared to normal non-senescent cells, and FOXO4 localizes to nuclear foci (promyelocytic leukemia bodies/DNA-SCARS) where it physically interacts with p53, retaining active p53 in the nucleus and preventing it from translocating to the mitochondria where it would execute transcription-independent apoptosis.
The consequence is that senescent cells are essentially locked in a state of apoptosis resistance by the FOXO4-p53 interaction — a molecular mechanism that keeps them alive and secreting SASP despite carrying the molecular signals that would normally condemn them to cell death.
FOXO4-DRI is designed to compete with endogenous FOXO4 for p53 binding, displacing FOXO4 from the interaction. When the FOXO4-p53 complex is disrupted, p53 is excluded from the nucleus and translocates to the mitochondria where it activates the BAX/caspase cascade, driving apoptosis selectively in senescent cells. Non-senescent cells are largely spared because FOXO4 is expressed at very low levels in non-senescent adult cells, meaning the interaction that FOXO4-DRI disrupts barely exists in normal healthy tissue.
Published Research
Study 1 — Foundational: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis
Authors: Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ Year: 2017 Journal: Cell PMID: Available via Cell DOI 10.1016/j.cell.2017.02.031 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5556182/
This foundational study published in Cell by researchers at Erasmus University Medical Center (with co-authors including Judith Campisi of the Buck Institute, a leading figure in senescence biology) established the proof-of-concept for FOXO4-DRI as a senolytic agent. The study used three in vivo senescence models: chemotoxicity-induced senescence via doxorubicin, accelerated aging in XpdTTD/TTD mice (a genetically accelerated aging model), and natural aging in wild-type mice.
In vitro selectivity: FOXO4-DRI produced an 11.73-fold greater reduction in viability of senescent IMR90 human fibroblasts compared to non-senescent control IMR90 cells, demonstrating potent and selective pro-apoptotic activity in senescent cells. Neither the same peptide in L-isoform nor an unrelated DRI-peptide based on a different forkhead protein (FOXM1) affected senescent cell viability, confirming both the importance of the DRI modification and the specificity of the FOXO4 target.
Apoptosis mechanism confirmed: Knockdown of p53 and co-incubation with pan-caspase inhibitors both reduced FOXO4-DRI’s ability to target senescent cells, confirming that the apoptotic activity is p53-dependent and caspase-mediated.
Accelerated aging model: Fast-aging XpdTTD/TTD mice showed accelerated hair loss, reduced exploratory behavior, and impaired kidney function. FOXO4-DRI treatment led to fur regrowth beginning at approximately 10 days. Running wheel activity in treated mice increased significantly within approximately 3 weeks, with treated animals running substantially further than untreated counterparts. Kidney function as measured by plasma urea was improved after approximately 1 month of treatment.
Natural aging model: In naturally aged wild-type mice, FOXO4-DRI induced strong apoptosis in senescent renal tubular cells detected by TUNEL assay within 3 days of treatment in ex vivo aged kidney slices, and restored kidney function markers in vivo over 30 days of treatment. FOXO4-DRI reduced IL-6 expression in aged kidney tissue — IL-6 being a major SASP factor indicating active senescent cell inflammatory activity.
Thrombocyte safety advantage: Unlike the pan-BCL-2 inhibitor senolytics (ABT-263/ABT-737) which cause severe thrombocytopenia (platelet reduction), FOXO4-DRI did not significantly affect platelet counts in treated animals — a meaningful safety advantage for systemic administration.
Long-term tolerability: Mice were treated for over 10 months with infusions three times per week without observed adverse effects, and normal reproduction was unaffected — consistent with the low expression of FOXO4 in non-senescent cells limiting off-target activity.
The authors concluded that FOXO4-DRI may be a potent drug to restore loss of health after natural aging and is an attractive option to explore in the battle against age-related diseases driven by senescence.
Study 2 — Senescent Chondrocyte Clearance for Cartilage Repair Applications
Authors: Zhu et al. (published in Frontiers in Cell and Developmental Biology) Year: 2021 Journal: Frontiers in Cell and Developmental Biology (PMC) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC8116695/
This independent study examined whether FOXO4-DRI could selectively remove senescent cells from in vitro expanded human chondrocytes — cells used in autologous chondrocyte implantation (ACI) procedures for cartilage repair, which generate increasing proportions of senescent cells during the expansion process required for clinical use.
Human chondrocytes were expanded to population doubling level 9 (PDL9, representing clinical-grade cells ready for implantation) versus PDL3 controls. PDL9 cells showed significantly elevated senescence markers by SA-beta-galactosidase staining and senescence-relevant gene expression.
FOXO4-DRI treatment significantly reduced cell number in PDL9 chondrocytes — removing more than half of the senescent cell population — while not significantly affecting cell viability in PDL3 (minimally expanded) control chondrocytes.
Apoptosis was confirmed as the mechanism of cell death in FOXO4-DRI-treated PDL9 cells by activated caspase-3/7 detection.
Cartilage tissue generated from FOXO4-DRI pretreated PDL9 cells displayed lower expression of senescence-associated secretory factors than untreated control, demonstrating that senescent cell clearance produced a measurable improvement in the inflammatory secretory profile of the remaining cell population.
The authors noted that while FOXO4-DRI successfully removed senescent chondrocytes, its utility in directly promoting cartilage formation from expanded cells requires further investigation, highlighting the distinction between senescent cell clearance and active tissue regeneration.
Study 3 — Senescent Leydig Cell Clearance and Testosterone Restoration
Authors: Zhang C, Xie Y, Chen H et al. (Sun Yat-sen University) Year: 2020 Journal: Aging (published by Impact Journals) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7053614/
This independent study from researchers in China extended the FOXO4-DRI senolytic concept to male gonadal aging, specifically examining whether FOXO4 expression in Leydig cells — the testicular cells responsible for testosterone synthesis — contributed to age-related testosterone decline, and whether FOXO4-DRI could restore gonadal function.
FOXO4 expression was confirmed in human Leydig cells, and its nuclear translocation in elderly subjects was associated with decreased testosterone synthesis — providing human tissue evidence for the relevance of the FOXO4 pathway in endocrine aging.
In hydrogen peroxide-induced senescent TM3 Leydig cells in vitro, FOXO4-DRI caused nuclear exclusion of active p53, disrupting the FOXO4-p53 interaction and driving selective apoptosis of senescent Leydig cells without affecting normal Leydig cell viability.
In naturally aged mice, FOXO4-DRI treatment improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency, demonstrating functional restoration of endocrine tissue through senescent cell clearance.
This study represents an important independent confirmation of FOXO4-DRI’s mechanism in a tissue type — gonadal Leydig cells — distinct from the kidney tubular cells and dermal fibroblasts studied in the original Baar et al. publication.
Study 4 — Keloid Pathological Scar Senescent Fibroblast Clearance
Authors: Published in Communications Biology (Nature Publishing Group) Year: 2025 Journal: Communications Biology PMID: 39994346 Full text: https://www.nature.com/articles/s42003-025-07738-0
This 2025 study published in a Nature group journal examined the role of senescent fibroblasts in keloid formation and tested FOXO4-DRI as a potential therapeutic approach for these pathological, treatment-resistant scars.
Single-cell RNA sequencing of keloid tissue revealed increased proportions of pro-inflammatory and mesenchymal fibroblast subpopulations, elevated senescence-associated secretory phenotype gene expression, elevated p16 protein, and a higher proportion of beta-galactosidase-positive senescent cells compared to normal skin.
Upregulated p53-serine15 phosphorylation (p53-pS15) was identified in keloids as the specific p53 form sequestered by FOXO4 in the senescent microenvironment.
FOXO4-DRI treatment promoted apoptosis and decreased G0/G1 phase cell populations in senescence models of both keloid fibroblasts in culture and in keloid organ culture models, accompanied by p53-pS15 nuclear exclusion — directly confirming the mechanism in pathological human scar tissue.
This study demonstrates extension of the FOXO4-DRI senolytic approach to a human-relevant pathological condition in which senescent cells drive fibrosis and tissue overgrowth, expanding the potential research applications beyond natural aging to specific age-associated and inflammatory tissue disorders.
Study 5 — Vascular Aging and Endothelial Cell Senescence
Authors: Published in Frontiers in Cell and Developmental Biology (PMC) Year: Published 2025 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12852416/
This study examined FOXO4-DRI’s effects on senescent vascular endothelial cells — cells lining blood vessels that are critical to vascular function — and its potential to delay vascular aging.
FOXO4-DRI was shown to effectively promote apoptosis in senescent endothelial cells by blocking the FOXO4-P53 interaction and facilitating P53 phosphorylation through the p53/BCL-2/Caspase-3 signaling pathway.
Injection of FOXO4-DRI in both naturally aged and D-galactose-induced aging mice effectively suppressed aortic aging and improved aortic vascular function.
FOXO4-DRI alleviated endothelial cell senescence induced by oxygen-glucose deprivation, suggesting a potential role in vascular protection following ischemic injury.
This study confirms FOXO4-DRI’s senolytic mechanism operates in vascular tissue and adds vascular aging to the growing list of contexts in which the FOXO4-p53 senolytic axis has been explored experimentally.
Senescence Biology Context — Why This Research Matters
The accumulation of senescent cells with age is now well established as a causal driver rather than merely a correlate of age-related tissue dysfunction. Landmark experiments in mice have demonstrated that genetic ablation of p16-positive senescent cells extends healthspan, delays multiple age-related pathologies, and in some mouse strains extends median lifespan. Pharmacological clearance of senescent cells using small molecule senolytics (the dasatinib and quercetin combination, navitoclax, and others) has produced similar beneficial effects in a range of animal models and limited human pilot studies.
FOXO4-DRI occupies a distinct mechanistic position in the senolytic landscape because it targets a protein-protein interaction (FOXO4-p53) rather than broadly inhibiting the anti-apoptotic BCL-2 family proteins or other pro-survival pathways shared between senescent and non-senescent cells. This distinction in mechanism is the source of its selectivity advantage over first-generation senolytics that carry significant off-target cytotoxicity, particularly the platelet toxicity associated with navitoclax.
Current Research Status and Critical Context
FOXO4-DRI is not approved by the FDA or any regulatory agency for any indication. No human clinical trials of FOXO4-DRI have been completed or published as of the date of this overview. All published efficacy data derives from cell culture studies and animal models, primarily mice.
The following important caveats apply to interpreting the current evidence base.
No human pharmacokinetic data: The half-life, tissue distribution, bioavailability, and clearance of FOXO4-DRI in humans are unknown. Mouse-to-human dose translation for a cell-penetrating peptide with novel DRI modification involves significant uncertainty.
No human safety data: Long-term safety in humans — including effects on wound healing (which depends on senescent cells for proper signaling), immune function (which depends on certain senescent states), and development — has not been assessed.
Senescent cell heterogeneity: Not all senescent cells express FOXO4 at levels sufficient to make them FOXO4-DRI-sensitive. Senescent cells induced by different stressors (replicative exhaustion versus oncogene activation versus chemotherapy) show variable FOXO4-p53 dependence, meaning FOXO4-DRI will not clear all senescent cells in a given tissue.
Theoretical concerns: Disrupting p53 regulation — even transiently and selectively — in any cell type raises theoretical concerns about genomic stability effects. The authors of the original Cell paper explicitly cautioned against permanent FOXO4 inhibition given FOXO4’s role in DNA damage repair. The transient pharmacological approach of FOXO4-DRI is argued to mitigate this concern, but long-term human data would be needed to confirm.
Human safety studies were planned following the 2017 publication, including a proposed safety trial in patients with glioblastoma multiforme (which shows high FOXO4 expression). The publication status of these studies is not reflected in the current available literature.
FOXO4-DRI is a first-in-class research tool that has substantially advanced understanding of the FOXO4-p53 senolytic axis and stimulated a growing body of follow-on research across multiple tissue types. Its significance for aging biology research is established. Its clinical translation remains to be determined.
Reconstitution Note
FOXO4-DRI is a cell-penetrating peptide containing D-amino acids. It should be reconstituted gently — avoid vigorous shaking or vortexing, which can cause peptide aggregation. Bacteriostatic water is the standard reconstitution solvent. FOXO4-DRI may take 5 to 10 minutes to dissolve fully at room temperature. After reconstitution, protect from light and store immediately at 2 to 8 degrees Celsius. Due to the sensitivity of reconstituted solutions, single-use aliquoting before storage is recommended to avoid repeated access to the same vial. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound and per the product datasheet. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the FOXO4-DRI product page: https://roguecompounds.com/product/foxo4-dri/